---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-007968"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T14:28:01.241640+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaxart reports FY2025 net income of $16.3M vs loss; revenue $237.3M; cash runway into Q2 2027

## Summary
- Net income $16.3M ($0.07 EPS) vs net loss $66.9M ($0.33 loss) in FY2024.
- Revenue $237.3M, up from $28.7M, driven by BARDA contract and Dynavax collaboration.
- Cash, equivalents & investments $63.8M; runway into Q2 2027.
- COVID-19 Phase 2b sentinel cohort data (400 subjects) expected early Q2 2026; main cohort topline Q4 2026.
- Published Phase 1 norovirus data shows passive antibody transfer to infants via breast milk; next trial dependent on partnership.

## SEC filing metadata
- accession: 0001437749-26-007968
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774926007968/0001437749-26-007968-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774926007968/vxrt20260311_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-007968
- JSON: https://secwatch.observer/filing/0001437749-26-007968.json
- Plain text: https://secwatch.observer/filing/0001437749-26-007968.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.